Translations:GLP1 poly-agonist peptides/4/en

GLP-1, GIP, and glucagon receptor triple agonists

Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist retatrutide found an average −24.2 percent weight reduction in the highest dosage group after 24 weeks.